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ABSTRACT
To study the role of FAK signaling complexes in promoting metastatic properties of 
prostate cancer (PCa) cells, we selected stable, highly migratory variants, termed PC3 
Mig-3 and DU145 Mig-3, from two well-characterized PCa cell lines, PC3 and DU145. 
These variants were not only increased migration and invasion in vitro, but were also 
more metastatic to lymph nodes following intraprostatic injection into nude mice. Both 
PC3 Mig-3 and DU145 Mig-3 were specifically increased in phosphorylation of FAK Y861. 
We therefore examined potential alterations in Src family kinases responsible for FAK 
phosphorylation and determined only Yes expression was increased. Overexpression 
of Yes in PC3 parental cells and src-/-fyn-/-yes-/- fibroblasts selectively increased 
FAK Y861 phosphorylation, and increased migration. Knockdown of Yes in PC3 Mig-3 
cells decreased migration and decreased lymph node metastasis following orthotopic 
implantation of into nude mice. In human specimens, Yes expression was increased 
in lymph node metastases relative to paired primary tumors from the same patient, 
and increased pFAK Y861 expression in lymph node metastases correlated with poor 
prognosis. These results demonstrate a unique role for Yes in phosphorylation of FAK 
and in promoting PCa metastasis. Therefore, phosphorylated FAK Y861 and increased 
Yes expression may be predictive markers for PCa metastasis.
INTRODUCTION
Increased migration of cancer cells is a key 
process in metastasis [1]. Alterations in the expression of 
numerous gene products through genetic and epigenetic 
changes have been shown to affect prostate cancer 
(PCa) cell migration. Many of these changes converge 
on extracellular matrix/tumor interactions that lead 
Oncotarget10176www.impactjournals.com/oncotarget
to signaling through Focal Adhesion Kinase (FAK), a 
central mediator of growth regulatory functions [2–4]. 
Major activators of FAK signaling include growth factor 
receptors and integrins, several of which are aberrantly 
expressed and shown to increase metastatic potential of 
PCa [5–9]. FAK has been shown to regulate cell survival, 
proliferation, angiogenesis, epithelial-to-mesenchymal 
transition, migration, and invasion [9–15], processes 
important in tumor progression and metastasis. These 
diverse biologic functions are mediated through the 
intrinsic FAK tyrosine kinase activity, as well as its role as 
a scaffolding protein [8, 16]. More recently, nuclear FAK 
has been shown to function as a co-transcription factor, 
increasing the expression of cyclin D1 and promoting p53 
and GATA4 degradation, processes that increase cellular 
survival and proliferation [17, 18]. Increased expression 
of FAK occurs in many solid tumors, with levels of 
expression generally increasing with tumor progression 
[19–24]. In PCa, FAK is overexpressed in more than 70% 
of tumors relative to normal tissue [10], and increased 
FAK expression correlates with tumor grade, with highest 
expression occurring in metastases [10, 25, 26]. As FAK 
inhibitors have reached clinical trials [10], understanding 
the mechanisms by which FAK signaling pathways are 
activated and how FAK contributes to PCa progression 
and metastasis is of important clinical relevance.
FAK activation occurs as a result of a conformational 
change in the FAK FERM domain [7], leading to 
autophosphorylation at tyrosine 397. Once phosphorylated, 
pFAK Y397 recruits numerous signaling molecules, 
including Src family kinases (SFKs), through their SH-2 
domains [7, 8]. Indeed, FAK was first identified as a 
substrate of the viral Src oncogene [27, 28]. Binding of 
SFKs to pFAK Y397 leads to trans-phosphorylation of 
multiple tyrosine sites in FAK, specifically, Y407, Y576, 
Y577, Y861 and Y925 [29]. Phosphorylation of these sites 
is responsible for “full” FAK catalytic activation as well as 
recruitment of multiple proteins directing signaling cascades 
that promote the  above-described biologic functions 
regulated by FAK [4, 29]. Thus, FAK-SFK association is 
essential for most FAK functions [30–33]. In PCa, multiple 
SFKs are constitutively activated [34–39], and play distinct 
roles in PCa initiation [37, 40] and progression [34, 39, 41]. 
Lyn activation is involved in prostate development [37]; 
increases PCa proliferation [34], and increased expression 
of Lyn regulates androgen expression and promotes 
castrate-resistant PCa progression [39]. Src activation does 
not affect proliferation to a similar extent [34], but does 
promote PCa migration and metastasis [42, 43]. Fyn is 
highly overexpressed in PCa [35], affects hepatocyte growth 
factor-directed chemotaxis and is therefore important in PCa 
progression [44]. Mutated, constitutively activated forms of 
Src, Lyn and Fyn also induce different biology in primary 
murine prostate epithelial tissue transformed by FGF 10 
[40]. Expression of activated Src kinase in these cells grown 
in the renal capsule led to characteristics associated with 
poorly differentiated, invasive adenocarcinoma; expression 
of activated Fyn led to PCa initiation by formation of 
prostate intraepithelial-like lesions and expression of 
activated Lyn had no obvious effect on prostate epithelial 
phenotypes [40]. Thus, strong evidence supports different 
roles of SFKs in PCa progression. Surprisingly, the effects 
of individual SFKs on FAK functions and how they may 
specifically affect PCa metastasis have not been previously 
examined. Further, potential roles of Yes, the closest 
related kinase to Src, which is also highly expressed in PCa 
cells [45], in promoting PCa progression, have not been 
examined prior to this study.
To examine potential roles of FAK-SFK complexes 
in mediating different properties of PCa metastasis, we 
used an unbiased strategy to select migratory variants 
of two well-studied PCa cell lines, PC3 and DU145, and 
examined changes in FAK phosphorylation, SFK expression 
and metastasis. Our results demonstrate that altered 
phosphorylation of FAK at a specific site, tyrosine 861, plays 
an important role in regulating key metastatic properties of 
PCa cells. We further identify a novel role of Yes in selective 
phosphorylation of FAK and in promoting PCa metastasis.
RESULTS
Isolation of highly migratory subclones of 
PCa cells
One of the principal roles of FAK-SFK complexes 
is regulating migration [4, 46, 47]. As numerous FAK 
activators and downstream signaling molecules are 
involved in this process, we developed highly migratory 
sublines of the prostate cancer cell lines PC3 and DU145 
by multiple cycles of in vitro selection for cells that had 
migrated in a modified Boyden chamber (see schema, 
Fig. 1A). As described in Materials and Methods, cells 
that had migrated through the Boyden Chamber were 
grown to confluency and re-migrated. This process was 
repeated three times. Migratory-selected cells were 
termed PC3 Mig-1, PC3 Mig-2, PC3 Mig-3, DU145 
Mig-1, DU145 Mig-2, and DU145 Mig-3, reflecting each 
cycle of selection (Fig. 1A). In vitro migration of these 
subclones was increased at each of the first three cycles 
of selection (Fig. 1B), with no further increases observed 
following subsequent selections (data not shown). The 
phenotype of the migratory variants has remained stable 
for more than 30 passages, the longest time examined. 
PC3 Mig-3 was increased in migration by 20 fold relative 
to PC3-P (PC3 parental) cells (Fig. 1B, p < 0.0001); 
DU145 Mig-3 cells were increased in migration by 6 fold 
(Fig. 1B) relative to DU145-P (DU145 parental) cells 
(p < 0.0001). As an independent measure of migration, 
time-lapse microscopy was performed for PC3-P and PC3 
Mig-3 isogenic cell lines, and the average speed of the 
populations is plotted (Fig. S1, upper panel) along with 
representative images indicating the distance traveled by 
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the cell populations in 24 hours (lower panel). Time-lapse 
movies of migration are shown in Videos S1 and S2. 
The speed of migration of PC3 Mig-3 was 0.08 ± 0.01 
μm/min, compared to 0.04 ± 0.006 μm/min in PC3-P cells 
(p < 0.001). These data confirm that PC3 Mig-3 cells are 
more migratory than PC3-P cells.
PC3 Mig-3 and DU145 Mig-3 cells have 
increased invasion, decreased attachment and 
decreased proliferation relative to parental cells
To investigate if the migratory selected cells were 
also more invasive, an in vitro invasion assay using a 
matrigel-coated Boyden chamber was performed. PC3 
Mig-3 cells were increased in invasion by 25 fold relative 
to PC3-P cells (p < 0.0001); DU145 Mig-3 cells had a 
4 fold increased invasion compared to DU145-P cells 
(p < 0.0001) (Fig. 1C), correlating with the increased 
migration in both cell models. To determine whether 
increased migration and invasion were due to differences 
in proliferation, 5 × 104 PC3-P, PC3 Mig-3, DU145-P 
and DU145 Mig-3 were plated in a 48 well plate. Viable 
cells were enumerated daily for six days. The doubling 
times for PC3-P cells and PC3 Mig-3 cells were 19 hours 
and 25 hours, respectively (Fig. S2). The doubling 
times for DU145-P and DU145 Mig-3 cells were 19 
and 24 hours, respectively (p < 0.05). These data are 
consistent with more migratory cells having reduced 
proliferation rates [48].
Next, the effects on cell attachment were analyzed 
by plating 5 × 104 cells in each well of a 96-well plate 
and washing with PBS after 30 minutes. The number 
of viable cells bound to the cell culture plate was 
determined using Calcein AM staining. Attachment of 
PC3 Mig-3 cells was decreased by 33% relative to PC3-P 
cells (Fig. 1D, p < 0.05). Attachment of DU145 Mig-3 
cells was decreased by 63% relative to DU145-P cells 
(Fig. 1D, p < 0.05).
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Figure. 1: Development and characterization of highly migratory variants of PCa cells. A. Schematic diagram of isolation 
of migratory variants using a modified Boyden chamber assay. B. In vitro migration and C. invasion after each selection was determined 
using the modified Boyden chamber (migration) or matrigel-coated modified Boyden chamber (invasion) for 24 hours. Migrated 
(or invaded) cells were counted microscopically in 5 optical fields per filter. Bars represent mean ± SD from triplicate assays. *p < 0.05, 
**p < 0.001, ***p < 0.0001 by Student’s t-test. D. Attachment assay was performed for the indicated cells for 30 minutes. Bar graph 
represents mean ± SD from two independent assays performed in triplicate. *p < 0.05 by Student’s t-test.
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Increased expression of pFAK Y861 is associated 
with increased migration of PC3 Mig-3 cells
Having established two isogenic models with 
increased migratory potential, we next assessed 
potential alterations in FAK. FAK expression and 
tyrosine phosphorylation at each site were determined. 
Expression of total FAK protein in PC3 Mig-3 (Fig. 2A) 
(immunoblot, left panel) and DU145 Mig-3 cells 
(Fig. 2B) (immunoblot, left panel) relative to the parental 
cells was similar. Phosphorylation of FAK Y397 (the 
autophosphorylation site) was not changed. However, 
phosphorylation of one of the SFK-dependent tyrosine 
sites, FAK Y861, increased with each cycle of migration 
selection in both PC3-P (Fig. 2A, immunoblots left 
panel; quantification right panel) and DU145-P cell lines 
(Fig. 2B, immunoblots left panel; quantification right 
panel), with no increase in other SFK-dependent tyrosine 
phosphorylation sites, i.e., FAK Y401, FAK Y577, FAK 
Y576 and FAK Y925.
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Figure. 2: Migratory variants of PCa cells have increased phosphorylation of FAK Y861. A. Expression of FAK and 
phosphorylation of individual FAK tyrosine sites on indicated cell lysates was determined by immunoblotting (left panel). Quantification 
(right panel). B. Identical analyses were performed in DU145 cells; immunoblot (left panel); quantification (right panel).
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Met and Axl do not contribute to increased 
migration of PC3 Mig-3 cells
We further examined the expression of two 
additional proteins, Met and Axl, which have also been 
shown to regulate migration and are overexpressed in 
prostate cancer progression [49, 50]. As shown in Fig. 3A, 
Met and Axl were also increased in migration-selected 
PC3 Mig-3 cells relative to PC3-P cells (compare lanes 
and 1 and 2). To examine if Axl and/or Met contributed to 
increased migration of PC3 Mig-3, single cell cloning of 
PC3 Mig-3 was performed. Expression of these proteins 
in five subclones is shown in Fig. 3A (lanes 3–7). Each 
clone consistently overexpressed pFAK Y861; however, 
Met and Axl were variably expressed, with some clones 
overexpressing either Met or Axl or both, and other 
clones overexpressing neither, relative to parental cells. 
To determine the potential contribution of Met and Axl 
to migration of these subclones, migration assays on each 
subclone were performed. As shown in Fig. 3B, all five 
PC3 Mig-3 subclones have increased migration relative 
to PC3-P cells; however, the levels of Met and Axl in 
these subclones did not alter in vitro migration. Thus, 
among the candidate migratory factors examined, the 
only consistent alteration that correlated with increased 
migration in all of the clones of PC3 Mig-3 cells was 
increased levels of pFAK Y861. Overexpression of 
Yes was also observed (experiments demonstrating the 
importance of Yes overexpression are described below). 
These results indicate that increased expression of pFAK 
Y861 is independent of Axl or Met expression and is the 
molecular alteration studied that is most closely associated 
with increased of PC3 Mig-3 cells.
To determine if the increase in the phosphorylation 
of FAK at Y861 is involved in the enhanced migration 
of PC3 Mig-3 cells, we overexpressed a non-
phosphorylatable V-5 tagged form of FAK (FAKY861F) 
in the PC3 Mig-3 cells. Expression of this mutant 
is demonstrated by immunoblotting for the V-5 tag 
(Fig. S3A). In vitro migration of PC3 Mig-3 FAKY861F 
cells was determined in a modified Boyden Chamber 
assay (Fig. 3C, photomicrographs of migrated cells, 
left panel; quantification, right panel). Migration 
was reduced by 90% in PC3 Mig-3 FAKY861F cells 
compared to the empty vector control (p < 0.001). 
To determine whether decrease in migration in PC3 
Mig-3 cells expressing FAKY861F were due to change 
in proliferation, growth rates were determined. As 
shown in Fig. S3B, proliferation rates of PC3 Mig-3 
FAKY861F cells were comparable to that observed for 
the empty vector control cells. As an additional control, 
we overexpressed a V-5 tagged wild type FAK in PC3-P 
cells. As shown in Fig. 3C (photomicrographs, left 
panel; quantification right panel), FAK overexpression 
increased migration of PC3-P cells 3 fold, considerably 
less than the 20 fold increased migration observed in 
PC3 Mig-3 cells relative to PC3-P cells. These data 
indicate that phosphorylation of FAK Y861 is critical in 
regulating migration of PCa cells.
Increase in yes expression and kinase 
activity correlates with increased migration 
in PC3 Mig-3 cells
Src family kinases (SFK’s) catalyze phosphorylation 
of all of the FAK tyrosine phosphorylation sites, excluding 
the autophosphorylation site (FAK Y397) [29]. Hence, 
we investigated the expression and activity of SFK’s in 
PC3 Mig-3 and DU145 Mig-3 cells relative to PC3-P 
cells. As shown in Fig. 4A, no increased expression of 
Src, Fyn and Lyn was observed (immunoblot, left panel; 
quantification, right panel). However, a 2.5 fold increase in 
Yes expression was observed in PC3 Mig-3 cells relative 
to PC3-P cells. Similarly, Yes expression was increased by 
2 fold in DU145 Mig-3 relative to DU145-P cells (Fig. 4B, 
immunoblot, left panel; quantification, right panel), with 
no increase in other Src family kinase members. As 
determined by qRT-PCR, c-yes mRNA was increased 
2.3 fold (p < 0.001) in the PC3 Mig-3 and 2 fold (p < 0.05) 
in DU145 Mig-3 cells relative to their respective parental 
cells (Fig. 4C). We next examined the kinase activity 
of the SFKs expressed in PC3 cells. For these studies, 
immunoprecipitation of individual SFKs was performed 
using specific antibodies to each protein followed by 
immunoblotting with an antibody to chicken Src pY416 
that recognizes the autophosphorylation sites (indicative 
of the activated form of the kinases) of all the SFKs 
examined. As shown in Fig. 4D, no increase in expression 
or autophosphorylation was observed for Src, Lyn and Fyn 
in PC3 Mig-3 cells relative to the PC3-P cells. However, 
Yes activity was increased by 3 fold in the more migratory 
PC3 Mig-3 cells relative to the PC3-P cells (Fig. 4D). 
These results suggest that increased expression of Yes is 
accompanied with increased total kinase activity in PC3 
Mig-3 cells.
Yes association with FAK is increased in PC3 
Mig-3 cells
As Yes expression and activity were increased in 
PC3 Mig-3 cells relative to the PC3-P cells, we next 
performed co-immunoprecipitation studies to determine 
whether there were increased Yes-FAK association 
in PC3 Mig-3 cells compared to the PC3-P cells. As 
shown in Fig. 5A (left panel), increased Yes association 
with pFAK Y397 was observed in the PC3 Mig-3 cells 
relative to the PC3-P cells (1.6 fold). In contrast, there 
was no obvious increase in association of Src with pFAK 
Y397 in PC3 Mig-3 cells relative to the PC3-P cells 
(Fig. 5A, right panel), indicating increased association 
of Yes with FAK is specific to the more migratory PC3 
Mig-3 cells.
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Yes kinase preferentially phosphorylates FAK 
Y861 in PC3 Mig-3 cells
As Yes overexpression in the migratory variants 
increases Yes/FAK complexes, we next investigated the 
role of Yes in phosphorylation of FAK Y861. As shown 
in Fig. 5B, overexpression of Yes in PC3-P cells increased 
FAK Y861 phosphorylation by 2.4 fold, and to a lesser 
extent FAK Y925 phosphorylation (1.4 fold, Fig. 5B, 
immunoblot, left panel; quantification, right panel). 
Yes overexpression did not increase phosphorylation 
of FAK Y397, FAK Y401, FAK Y577 and FAK Y576 
(Fig. 5B, immunoblot, left panel; quantification, right 
panel). In contrast, overexpression of Src in PC3-P cells 
led to an increased phosphorylation of all SFK sites 
(Fig. S3C).
In a second approach to determine if Yes 
preferentially phosphorylated FAK Y861, Yes was silenced 
in PC3 Mig-3 and DU145 Mig-3 cell lines cells using two 
pLKO.1 vectors directing the expression of Yes specific 
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Figure. 5: PC3 Mig-3 cells are increased in FAK association with Yes and Yes preferentially phosphorylates FAK Y861 in 
PC3 and SYF MEF cells. A. FAK-Yes and FAK-Src complexes were examined by immunoprecipitating with antibodies specific to Yes 
(left panel) or Src (right panel), followed by immunoblotting with antibodies to pFAK 397, Yes (left panel); Src (right panel) and total FAK. 
B. Effect of Yes overexpression on FAK phosphorylation of individual FAK tyrosine sites. Empty vector was used as a control (left panel). 
Quantification of immunoblotting normalized to vinculin (right panel). Representative data are shown from three independent experiments. 
C. FAK phosphorylation at individual tyrosine sites was determined by immunoblotting (left panel) after silencing Yes, using two different 
shRNA sequences (shYes#1006 and shYes#1611). A non-targeting (NT) plasmid was used as a control. Quantification of phosphorylation of 
FAK at individual tyrosine sites was performed and normalized to vinculin (right panel). D. Phosphorylation of FAK at individual tyrosine 
sites by Src or Yes in src-/-yes-/-fyn-/- mouse embryonic fibroblasts cells was determined by immunoblotting after overexpression of Yes or Src 
following transfection (left panel). Quantification of phosphorylation of FAK at individual tyrosine sites normalized to vinculin (right panel).
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shRNA sequences. In PC3 Mig-3 cells, knockdown of Yes 
led to decreased expression of pFAK Y861 (4 fold and 
2.6 fold) and to a lesser extent pFAK Y925 (2 fold and 
1.6 fold), with no significant effect on phosphorylation 
of the other FAK tyrosine residues, as shown in Fig. 5C 
(immunoblot, left panel; quantification, right panel). In 
contrast, silencing Src led to decreased phosphorylation 
of all the SFK phosphorylated FAK tyrosine residues 
(Fig. S3D). Similarly, silencing Yes in DU145 Mig-3 cells 
lead to decreased phosphorylation of FAK Y861 (Fig. S4A, 
immunoblotting, left panel; quantification, right panel). 
While the above experiments provided strong evidence 
that Yes kinase preferentially phosphorylates FAK Y861 
relative to the other FAK tyrosine sites, these experiments 
could not exclude potential roles of other SFKs expressed 
in PCa cells. Therefore, to further determine whether Yes 
is restricted in its ability to phosphorylate FAK, Yes or 
Src were transiently overexpressed in SYF (src-/-yes-/-
fyn-/-) mouse embryo fibroblasts. Overexpression of Src 
(alone) in the SYF cells led to increased phosphorylation 
of all the SFK-dependent tyrosine phosphorylation sites 
(Fig. 5D). However, overexpression of Yes led to a 
2.3 fold increase in phosphorylation of FAK Y861 with a 
minor increase in phosphorylation of FAK Y925 (Fig. 5D, 
immunoblot, left panel; quantification, right panel); no 
other SFK sites were appreciably phosphorylated. These 
data are consistent with a novel and restricted role of Yes 
in preferentially phosphorylating FAK Y861, and to a 
lesser extent, FAK Y925.
Yes expression affects migration of PCa cells
The above results suggested that increased 
Yes expression and activity were responsible for the 
observed effects on FAK Y861 phosphorylation. To 
examine if increased Yes expression directly affected 
PCa cell migration, we performed migration assays 
in PC3-P cells, PC3-P cells overexpressing Yes and 
in PC3 Mig-3 and DU145 Mig-3 cells in which Yes 
was silenced. Overexpression of Yes in PC3-P cells 
led to a 3.4 fold (p < 0.0001) increase in migration 
(Fig. 6A, photomicrographs of migrated cells, upper 
panel; quantification, lower panel), while knockdown 
of Yes in PC3 Mig-3 cells led to a 50% (shYes#1006, 
p < 0.0001) and 57% (shYes#1611, p < 0.0001) 
reduction in migration relative to non-targeting PC3 
Mig-3 control cells (Fig. 6B, photomicrographs of 
migrated cells, upper panel; quantification, lower 
panel). Similarly, knockdown of Yes in DU145 Mig-3 
cells led to a 94% (shYes#1006, p < 0.0001) and 91% 
(shYes#1611, p < 0.0001) reduction in migration relative 
to the non-targeting virus-infected DU145 Mig-3 cells 
(Fig. S4B). Collectively, these data demonstrate that 
Yes phosphorylation of FAK Y861 corresponds with 
increased migration of both migratory variants, PC3 
Mig-3 and DU145 Mig-3.
PC3 Mig-3 cells induce increased lymph node 
metastases relative to PC3-P cells in orthotopic 
nude mouse models
As the selected migratory cells demonstrated 
several properties associated with increased metastasis, 
we investigated the metastatic potential of PC3 Mig-3 
cells by inoculating cells into the prostate of nude mice 
(the orthotopic site) as described in Materials & Methods. 
Mice were sacrificed after 4 weeks. All mice developed 
primary tumors (see Table 1). In agreement with in vitro 
growth rates, PC3 Mig-3 tumors at similar inocula were 
smaller in size (p < 0.001) (Fig. S5A) and had fewer Ki67 
positive cells relative to the PC3-P (p < 0.05) (Fig. S5B; 
photomicrograph of Ki67 positive cells, upper panel; 
quantification, lower panel). Lymph node metastases 
(orthotopic injection models lead to lymph node, but not 
distant metastases) were assessed by identifying solid, 
opaque and enlarged iliac lymph nodes. An example of a 
tumor-positive lymph node for both PC3-P and PC3 Mig-3 
cells before complete dissection is shown in Fig. S6A. 
Insets show examples of enlarged nodes with white 
appearance (20X magnification). Representative primary 
tumors and lymph node metastases from five mice after 
complete dissection are shown in in Fig. S6B. Presence 
of tumor cells in the node was histologically confirmed 
using H&E staining as indicated in photomicrographs of 
representative lymph node metastases shown in Fig. S7A, 
and S7B, left panels. Despite significantly smaller primary 
tumors obtained from 125,000 PC3 Mig-3 cells relative to 
125,000 PC3-P cells (p < 0.05), the number of lymph node 
metastases was increased in mice injected with PC3 Mig-3 
cells (p < 0.05) (Table 1). To obtain similar-sized primary 
tumors from PC3-P and PC3 Mig-3 to most accurately 
compare development of lymph node metastases, we 
increased the inocula of PC3 Mig-3 tumor cells implanted 
intraprostatically. An initial inoculum of 125,000 PC3-P 
cells and 500,000 PC3 Mig-3 cells gave statistically 
similar primary tumor sizes (See Fig. 7A, Table 1 and 
Fig. S6B). The average number of lymph node metastases 
when primary tumors were of similar size was 4.1 ± 0.3 
in the PC3 Mig-3 group relative to 1.5 ± 0.3 lymph node 
metastases in PC3-P tumors (p < 0.001) (Fig. 7B). These 
data demonstrate that PC3 Mig-3 cells are more metastatic 
relative to the PC3-P cells.
Increased expressions of pFAK Y861 and Yes 
kinase are associated with PCa lymph node 
metastases in an orthotopic nude mouse model
As discussed above, PC3-P cells are also able 
to metastasize to the lymph node following orthotopic 
injection, albeit to a lesser extent. We therefore determined 
if the lymph node metastases from PC3-P also exhibited 
increased phosphorylation of FAK Y861 and increased 
expression of Yes kinase. pFAK Y861 and Yes expression 
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Figure. 6: Yes regulates migration of PC3 cells. A. Effect of overexpression of Yes on migration of PC3-P cells. Representative 
photomicrographs of migrated cells (upper panel). Bars represent means ± SD (lower panel). ***p < 0.0001 by Student’s t-test of three 
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in the primary tumors and lymph node metastases was 
assessed by immunohistochemistry. Quantification of the 
staining was performed after randomly selecting areas 
from the whole tumor scans from the primary tumors and 
lymph node metastases. Examples of lymph nodes stained 
for pFAK Y861 are shown in Fig. S7A and S7B (right 
panels). Magnified random sections (20X, insets) indicate 
examples of representative areas used in quantification. 
As expected, in PC3 Mig-3 primary tumors, pFAK Y861 
expression was increased 2.5 fold relative to PC3-P 
primary tumors (p < 0.001) (Fig. 7C, compare panel 3 to 
panel 1, quantification Fig. 7D top panel). However, levels 
of pFAK Y861 in the lymph node metastases from PC3-P 
cells were also increased relative to primary tumors, to 
levels similar to those observed in PC3 Mig-3 primary 
tumors and lymph node metastases (Fig. 7C, compare 
panel 2 to panels 3 and 4, quantification Fig. 7D top panel). 
These results demonstrate that lymph node metastases are 
associated with increased pFAK Y861. We next examined 
Yes expression in PC3-P primary tumors and lymph node 
metastases. Similar to what was observed for pFAK Y861, 
Yes expression was increased by 2.3 fold in PC3-P lymph 
node metastases compared to PC3-P primary tumors 
(p < 0.001) (Fig. 7C, compare panel 1 to panel 3) with no 
further increase in expression of Yes in PC3 Mig-3 lymph 
node metastasis relative to PC3 Mig-3 primary tumor 
(Fig. 7C; compare panel 3 to panel 4; quantification of 
IHC, Fig. 7D bottom panel). Additionally, Yes expression 
in the lymph node metastasis relative to the primary 
tumors was also determined at the RNA levels using qRT-
PCR. Lymph node metastases from PC3-P tumors were 
increased in expression of Yes relative to the primary 
tumors (Fig. S8). These observations suggest that increased 
phosphorylation of FAK Y861 and increased expression of 
Yes are associated with PCa lymph node metastases.
Yes promotes PCa lymph node metastasis in the 
orthotopic nude mouse model
The above studies suggested that increased Yes 
expression might be responsible for the observed increase 
in lymph node metastases in our migratory-selected 
variants. Therefore, PC3 Mig-3 cells in which Yes was 
silenced were examined for the development of lymph 
node metastases after orthotopic implantation into the 
prostates of nude mice. For these experiments, Non-
targeting control (NT) and Yes-silenced cell lines with 
two different sequences were transduced with a plasmid 
directing luciferase expression. Following orthotopic 
injections, mice were sacrificed when the primary tumors 
reached similar sizes (Table 2, Fig. 7E, left panel). 
Lymph node metastases were formed in all the groups 
(Table 2). However, decreased Yes expression decreased 
development of lymph node metastases. Control NT PC3 
Mig-3 cells formed 3.5 ± 0.2 lymph node metastasis 
compared to 1.8 ± 0.3 lymph node metastases in the 
shYes#1006 group (p < 0.001) and 1.6 ± 0.2 lymph node 
metastases in the shYes#1611 group (p < 0.0001) (Fig. 7E, 
right panel). Therefore, silencing Yes in PC3 Mig-3 cells 
decreased their ability to metastasize to lymph nodes, 
indicating that Yes is important to this metastatic process.
Yes and pFAK Y861 expression in human 
prostate cancer specimens
We next examined pFAK Y861 expression in 
lymph node metastases of prostate cancer patients using 
immunohistochemistry. Phosphorylated FAK Y861 
was observed in tumor-positive lymph nodes in 50% of 
specimens (n = 20). Representative images of lymph node 
metastases are shown in Fig. 8A. Patients with positive 
or high pFAK Y861 expression had an overall survival of 
6.1 ± 1.0 years. In contrast, patients with negative or low 
pFAK Y861 expression had an overall survival of 11.7 ± 
1.7 years, (p = 0.008) (Fig. 8B). These data indicate that 
expression of pFAK Y861 in prostate cancer patients 
correlates with decreased survival.
Next, we examined Yes protein expression in PCa 
primary tumors and matching lymph node metastases 
(n = 10) by immunohistochemistry. Representative 
photomicrographs of a primary tumor and corresponding 
lymph node metastasis are shown in Fig. 8C (left panel). 
Yes expression in every lymph node metastasis was 
significantly increased relative to its corresponding primary 
Table 1: Average weight of primary tumor and lymph node metastasis following orthotopic 
injection of PC3-P and PC3 Mig-3 cells
Group Average Tumor wt. 
(mg)/range
Incidence of primary 
tumor
Average number of 
LN mets/range
Incidence of LN mets
PC3-P (125,000) 598.5 (220–875) 9/9 1.8(1–3) 9/9
PC3 Mig-3 (125,000) 183.1 (45–349)* 7/7 2.7(2–4)* 7/7
PC3 Mig-3 (250,000) 339.5 (204–490) 7/7 2.6(1–3)* 7/7
PC3 Mig-3 (500,000) 423.5 (303–730) 7/7 4.1(3–5)* 7/7
Abbreviation LN mets: Lymph node metastases
*p < 0.05 by Tukey’s test compared to PC3-P (125, 000)
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Figure. 7: Increased phosphorylation of FAK Y861 and increased expression of Yes promotes lymph node metastasis 
of PC3 Mig-3. A. Weights of PC3-P and PC3 Mig-3 tumors following intraprostatic injection of 125,000 PC3-P cells and 500, 000 PC3 
Mig-3 cells (6 mice/group). Graph represents average tumor weight ± SEM from PC3-P and PC3 Mig-3 cells. N.S-no statistical difference. 
B. Number of lymph node metastases in the above-described experiment is represented as mean ± SEM. **p < 0.001 by Tukey’s 
test. C. Expression of pFAK Y861 and Yes in fixed sections of primary tumors and lymph node metastasis from PC3-P and PC3 Mig-3 
as determined by immunohistochemistry (left panel); corresponding H&E are shown below. D. Quantification of staining- pFAK Y861 
(top panel), Yes (bottom panel). Bars represent average intensity ± SD. **p < 0.001 by Student’s t-test. (D) Effect of Yes silencing on 
lymph node metastasis of PC3 Mig-3 cells (6 mice/group). Graph represents average tumor weight ± SEM. N.S-no statistical difference. 
E. Number of lymph node metastasis represented as mean ± SEM. **p < 0.001, ***p < 0.0001 by Tukey’s test.
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Table 2: Average weight of primary tumor and lymph node metastasis following orthotopic 
injection of NT PC3 Mig-3, shYes#1006 PC3 Mig-3 and shYes#1611 PC3 Mig-3 cells
Group Average Tumor wt. 
(mg)/range
Incidence of primary 
tumor
Average number of 
LN mets/range
Incidence of LN mets
NT PC3 Mig-3 556.7 (490–670) 6/6 3.5 (3–4) 6/6
shYes #1006 PC3 
Mig-3 572.8 (436–694) 6/6 1.8 (1–3)** 6/6
shYes #1611PC3 
Mig-3 604.7 (494–687) 6/6 1.6 (1–3)** 6/6
Abbreviation LN mets: Lymph node metastasis
**p < 0.001 by Tukey’s test relative to NT PC3 Mig-3
tumor (p < 0.05) as indicated by the matching colors for 
primary tumor and corresponding lymph node metastasis 
in the graph (Fig. 8C, right panel). Yes expression was 
increased by an average of 3.2 fold in the lymph node 
metastases relative to the primary tumors (p < 0.05) 
(Fig. 8C). In addition to detection in PCa cells, high Yes 
expression was observed in lymphocytes. Lymphocyte 
expression of Yes was excluded in quantitation of changes 
in tumor cells. Therefore, both Yes and its principal FAK 
target (pY861) are increased in lymph node metastasis, 
suggesting their importance in PCa metastasis.
DISCUSSION
We demonstrate that overexpression of Yes in our 
model migratory cell lines increases Yes/FAK association, 
which is responsible for increased phosphorylation of 
FAK Y861, leading to increased cell migration in vitro 
and metastasis in vivo (see model Fig. 8D). FAK is a 
mediator of numerous biologic properties that when 
deregulated are associated with increased metastatic 
potential [51, 52]. Additionally, many of the proteins in 
signaling cascades activated through the adaptor functions 
of FAK are aberrantly expressed in cancer cells, several of 
which also induce increased metastatic potential [9, 10, 
52, 53]. In prostate cancer, FAK is overexpressed, with 
overexpression correlating with higher tumor grade and 
metastasis [25, 26]. Overexpression of numerous growth 
factor receptors [54–57] and constitutive activation of 
integrins [56] and activators of integrins [58] in prostate 
cancer increase FAK functions and increase metastasis in 
immunodeficient mouse models. Autophosphorylation of 
FAK leads to association with multiple Src family kinases 
[43, 59], which are themselves constitutively activated in 
progressive stages of PCa [34, 45], and are responsible 
for phosphorylation of tyrosine residues on FAK that 
derepress FAK adaptor functions leading to aberrant 
activation of signaling cascades that increase metastatic 
potential. In prostate cancer cells, increased FAK-Src 
signaling is associated with migration of PC3 and DU145 
PCa cells [31], but the roles of phosphorylation of each 
of the individual FAK sites and the signaling cascades 
activated were not examined previously.
Numerous studies have analyzed the complexes 
associated with FAK tyrosine phosphorylation sites, 
and the functions that they mediate [60–63]. Yet, 
very few studies have examined if alterations in FAK 
phosphorylation might contribute to FAK functions 
associated with metastasis. Lim et al. demonstrated 
that phosphorylation of FAK at Y861 was important to 
Ras transformation of fibroblasts [60], and increased 
Src activity was associated with increased FAK 
phosphorylation and increased migration in tamoxifen-
resistant MCF breast cancer cells [64]. However, the 
mechanisms by which these altered phosphorylations 
occur and their potential roles in metastatic capability are 
unknown.
Therefore, to better unravel roles of altered FAK 
regulation in promoting migration, a key property in 
metastasis, we established stable isogenic models of 
prostate cancer cell lines with increased migration through 
a modified Boyden Chamber selection assay. In both PC3 
and DU145 cells selected by this strategy, a signature 
alteration associated with increased migration of cells 
is increased phosphorylation of FAK Y861. We asked 
whether there were changes in expression/activity of SFKs 
that might account for the altered FAK phosphorylation. 
We demonstrate, for the first time, that Yes phosphorylates 
only FAK Y861 and FAK Y925, unlike Src, which directs 
phosphorylation of each of the known phosphorylated FAK 
tyrosine residues besides Y397. These results demonstrate 
that different Src family kinases have distinct abilities 
in phosphorylating FAK sites that mediate signaling 
cascades associated with metastasis. Interestingly, it was 
reported that overlapping downstream signaling pathways 
of FAK Y861 and FAK Y925 can compensate for one 
another in mediating migration of cells via recruitment 
of p130Cas, formation of complexes with Crk/DOCK180 
and activation of Rac GTPases, promoting lamelipodia 
and invadopidia formation [60, 62]. This functional 
overlap may explain why pFAK Y925 expression was 
not increased in our migratory selected isogenic variants. 
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Figure. 8: Expression of pFAK Y861 and Yes in PCa patients. A. Expression of pFAK Y861 in lymph node metastasis from 
patient tumors by immunohistochemistry. B. Kaplan-Meier survival plot. Average survival time of cases with high pFAK Y861 expression: 
6.1 ± 1 years with low pFAK Y861: 11.7 ± 1.7 years; p = 0.008 by log rank test. C. Expression of Yes in paired primary tumors and lymph 
node metastases from prostate cancer patients by immunohistochemistry. Representative photomicrographs in primary tumor (upper right 
panel) and corresponding lymph node metastasis (upper left panel). Corresponding H&E are shown in lower panels. Bars represent the 
average fold-change ± SEM in Yes expression in primary tumor compared to corresponding lymph node metastases, with matching colored 
data points indicating primary tumor and corresponding lymph node metastasis (right panel). *p < 0.05 by Student’s t-test. D. Model 
for restrictive phosphorylation of FAK Y861 and FAK Y925 by Yes in the PC3 Mig-3 cells. 1) Integrin clustering and/or growth factor 
receptor activation lead to phosphorylation of FAK Y397. 2) pFAK Y397 recruits SFKs via their SH2 domain. 3) SFKs phosphorylate 
FAK at specific tyrosines, recruiting signaling proteins important to FAK’s scaffolding function. 4) PCa progression leads to increased 
transcription and expression of Yes, leading to preferential binding of Yes to pFAK Y397. 5) Yes binding to pFAK Y397 leads to preferential 
phosphorylation of FAK Y861 and to a lesser extent, FAK Y925 increasing migration, invasion and metastatic potential of PCa cells.
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As Src is highly activated in these prostate cancer cell lines 
[34], it may be that Src phosphorylation of FAK Y925 is 
sufficiently robust such that Yes cannot further increase 
FAK Y925 phosphorylation; hence increased FAK Y925 
phosphorylation was not observed in our selected cells. 
We did not detect an increased expression of FAK, which 
was reported to be associated with more progressed stages 
of PCa [25, 26]. We speculate that at least one role of 
increased expression of FAK observed in progressive 
stages of PCa might be to provide more tyrosine-
phosphorylated docking sites for proteins involved in 
signaling cascades that mediate metastatic potential. As 
FAK is also a co-transcription factor directing degradation 
of p53 [17] and expression of cyclin D1 [18], and leads to 
degradation of GATA 4 and p53, another possible role for 
overexpression of FAK is its nuclear function that leads 
to, among other properties, increased proliferation. Further 
experiments are required to resolve these possibilities.
To begin to address the mechanism by which Yes 
is upregulated in highly migratory cells, a cDNA array 
analysis was done comparing mRNA expression between 
PC3-P and PC3 Mig-3 cells (collaboration with Dr. David 
McConkey and Dr. Woonyoung Choi at UT MD Anderson 
Cancer Center; Houston; TX). Several transcription 
factors, including c-MYC, FOXA1 and HEY1 with binding 
sites on the Yes promoter region were overexpressed in the 
migratory variants (data not shown), suggesting a possible 
mechanism for Yes overexpression that will require further 
testing.
To examine whether the observations in our model 
system are clinically relevant, we assessed Yes and 
pFAK Y861 expression in human specimens from PCa 
lymph node metastasis compared to the corresponding 
primary tumor by immunohistochemistry. Our results 
demonstrated that pFAK Y861 was not only increased 
in a subset of lymph node metastases, its increase 
corresponded with poorer patient prognosis. Further, in 
patients in which paired primary tumors and lymph node 
metastases could be obtained, Yes expression was also 
increased. Increases in Yes expression observed in our 
immunohistochemical analysis were similar to increases 
in Yes mRNA expression observed by Varambally et al. 
[65], although in that study statistical significance was 
not achieved likely due to insufficient number of tissues 
examined. These data support the biological relevance of 
the model systems we developed, and implicate increased 
Yes expression and pFAK Y861 expression as potential 
prognostic markers. Although FAK can be phosphorylated 
by multiple Src family kinases, the striking increase of 
pFAK Y861 in lymph node metastases and its correlation 
with poor prognosis would suggest that high expression 
of FAK Y861 in primary tumors might be an especially 
useful marker for more aggressive treatment, as when 
patients with primary tumors should undergo “active 
surveillance” versus treatment is often uncertain. Whether 
pFAK Y861 should be used in conjunction with high Yes 
expression in this regard requires analysis of many more 
specimens. Finally, lymph node metastases were examined 
specifically as bone metastases are not observed in our 
orthotopic model. Future studies are planned to determine 
if increased Yes expression and its ability to increase FAK 
Y861 phosphorylation play a role in development of bone 
metastases.
In summary, we demonstrated the importance of 
phosphorylation of FAK Y861 in metastasis of PCa and 
further identified differences in the ability of SFKs to 
phosphorylate FAK, with Yes restricted to phosphorylating 
only FAK Y861 and FAK Y925. Our results demonstrate 
a heretofore-unknown role of Yes in promoting PCa 
metastasis, as well as the importance of pFAK Y861 in 
regulation of PCa migration.
MATERIALS AND METHODS
Cell culture
The PC3 cell line was a gift from the laboratory of 
Dr. Isaiah J. Fidler, and was maintained in DMEM F-12 
medium (Hyclone, USA) supplemented with 10% FBS 
(Hyclone, USA). The DU145 cell line was a gift from the 
laboratory of Dr. Renata Pasqualini and was maintained in 
RPMI 1640 (Corning CellGro, USA) supplemented with 
10% FBS (Hyclone, USA). SYF (src-/- yes-/- fyn-/-) mouse 
embryonic fibroblasts were obtained from the American 
Type Tissue Culture Collection, Manassas, VA, USA) and 
grown in DMEM media containing 10% FBS, glutamine 
and pyruvate. Cells were checked every six months for 
Mycoplasma contamination (MycoAlert™ Mycoplasma 
detection kit, Lonza, USA), and found to be mycoplasma-
free. Identity of cells was confirmed by fingerprinting 
analysis by the MD Anderson Cancer Center Department 
of Systems Biology, Core Facility.
Migration and invasion assays
Migration and Invasion abilities of the PC3 and 
DU145 cells were determined by the modified Boyden 
chamber migration assay as described by Lesslie et al. [66].
Time-lapse microscopy and quantification of cell 
migration
Subconfluent tumor cells were detached with 2 mM 
EDTA (Ambion #AM9260G), embedded (33,000/100 μl) 
in 3D fibrillar collagen lattices (PureCol, Advanced 
BioMatrix, Catlog #5005-B; final concentration 1.7 mg/ml). 
To construct the migration chamber, an object slide and 
a coverslip were connected by a spacer composed of 
vaseline / paraffin (1:1), resulting in an approximate 
chamber size of 20 × 20 × 0.5 mm and a volume of 
~200 μl. After addition of medium, spontaneous migration 
was monitored by digital time-lapse, bright-field inverse 
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microscopy (air objectives, 10x, NA 0.20; Leica) at 37°C 
using CCD cameras (Sentech, USA) and the 16-channel 
frame grabber software (Vistek, CA) for 24 hour with 
4-min frame intervals. Time-resolved population speed was 
obtained by single-cell tracking (Autozell 1.0 software; 
Centre for Computing and Communication Technologies 
[TZI], University of Bremen, Bremen, Germany) of xy 
paths with 12-min step intervals (tumor cells). The average 
speed per cell was calculated from the length of the path 
divided by time, including “go” and “stop” phases.
Cell attachment assays
PC3 and DU145 cells (5 × 104 cells/100 μL) 
were seeded into each well of a 96 well plate and were 
incubated for 30 minutes at 37°C after which the wells 
were washed with PBS three times and incubated with 
1 μmol/L Calcein AM (Invitrogen Life Technologies, 
USA) for 3 minutes. The cells that attached to the plate 
were quantified by measuring the fluorescence intensity 
at 458/528 nm in each well on a Synergy HT fluorescent 
plate reader (BioTeK, USA). All experiments were 
performed in triplicate.
Proliferation assays
Cells were seeded (5 × 103 cells/well) in 6-well 
tissue culture dishes. At 24 hour intervals, the media was 
removed, cells were trypsinized using TrypLE dissociation 
reagent (Gibco, USA). The cell suspension (500 μl) 
was counted using an automated cell viability analyzer 
Vi-Cell XR (Beckman Coulter, USA). All experiments 
were performed in triplicate.
Immunoblotting and immunoprecipitation
Immunoblotting was performed as described by 
Summy et al. [67]; immunoprecipitation as described by 
Windham et al. [68]. Antibodies used in the studies are 
shown in Table S1.
RNA isolation and quantitative real-time  
RT-PCR (qRT-PCR)
RNA was isolated from the cells using RNAeasy™ 
mini kit (Catalog # 74104, Qiagen, USA), as described by 
Varkaris et al. [69]. The primer sequences for Yes were 
forward: 5′-TCCTGCTGGTTTAACAGGTGGTG-3′ and 
reverse: 5′-TGCTTCCCACCAATCTCCTTCC-3′.
Lentiviral-mediated FAKY861F expression
The FAK Y861F and empty vector plasmids were 
constructed using the pLenti6/V5 plasmid from Invitrogen, 
USA. These plasmids contain a blasticidin-resistance 
gene and a gene encoding V5 tagged mutant FAK Y861F. 
PC3 Mig-3 cells were infected with the lentivirus in the 
presence of 4 μg/mL polybrene (Sigma, USA). After 
24 hours of infection, the media was replaced with DMEM 
F-12 and RPMI 1640 containing 10 μg/ml Blasticidin Hcl.
Lentivirus-mediated Yes and Src silencing
Mission shRNA bacterial glycerol stock 
plasmids for Yes were purchased from Sigma-Aldrich. 
Sequences used for Yes were TRCN0000001611: 
CCGGACCACGAAAGTAGCAATCAAACTCGAGTT 
TGATTGCTACTTTCGTGGTTTTTT and TRCN00000 
10006: CCGGTGGTTATATCCCGAGCAATTACTCG 
AGTAATTGCTCGGGATATAACCATTTTT. A non-
targeting control from Sigma (Cat.#SHC016): 
CCGGGCGCGATAGCGCTAATAATTTCTCGAGAAA 
TTATTAGCGCTATCGCGCTTTT was used along 
with the shRNA plasmid. For silencing Src, ready-
to-transfect short hairpin (sh) RNA-GFP-puromycin 
constructs against Src (#SR304574) were purchased 
from OriGene Technologies, USA. A universal scrambled 
negative control shRNA (#SR30004) was provided 
by the manufacturer. For lentivirus production (shYes 
plasmids), the pLKO.1 plasmid (3 μg) was co-transfected 
with the packaging plasmid pCMV-dR8.2 dvpr (3 μg) 
and the envelope plasmid pCMV-VSV-G (0.6 μg) in a 
ratio of 5:5:1 into 293FT cells in one 100-mm plate (Life 
Technologies, USA) using Lipofectamine™ 2000 (Life 
Technologies, USA) as describer by Jin et al. [58]. The 
medium was changed after 24 hours and replaced again 
with 5 μg/ml puromycin after 48 hours and incubated for 
one week to select stable cells in which expression of Yes 
was silenced.
Yes and Src overexpression
Yes was transiently overexpressed in the PC3-P cells 
using the pCMV6-XL5 Yes expression plasmid (Catalog 
# SC116734, OriGene Technologies, Inc., USA). Empty 
vector control was provided by the manufacturer (Catalog 
#pCMV6-XL5). The Yes plasmid was sequenced using 
VP1.5 (forward) 5′ GGACTTTCCAAAATGTCG 3′ and 
XL39 (reverse) 5′ ATTAGGACAAGGCTGGTGGG 3′. 
For overexpression of Src, the Src sequence was excised 
and cloned into the HindIII/BamHI cloning site of 
pCDNAIII (Invitrogen, USA), thus allowing for selection 
of G418-resistant clones as described by Windham 
et al. [68]. This plasmid was transfected into PC3 cells 
and SYF MEFs using jetPRIME™ (Polyplus-transfection, 
USA) according to manufacturer’s instructions.
Immunohistochemical staining and 
quantification
Immunohistochemistry was performed as described 
by Jin et al. [58] and quantified as described by Park 
et al. [34]. Briefly, stained primary tumors and lymph node 
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metastases we scanned under 10X magnification. Five 
representative images were taken at random and brown 
colored images specific for DAB staining were extracted by 
the color deconvolution macro, inversed, and measured for 
intensity using NIH imageJ internal commands, as we and 
others have published previously. pFAK Y861 staining in 
human specimens were scored as positive if > 10% of cells 
were reactive and negative if < 10% of cells were reactive.
In vivo tumorigenicity assay
PC3-P and PC3 Mig-3 cells were detached from 
subconfluent cultures, centrifuged and resuspended in 
Ca2+-free and Mg2+-free HBSS (Life Technologies, USA). 
Intraprostatic injections were performed as described by 
Park et al. [70]. Male athymic nude mice (Ncr nu/nu; 
ages 8–12 weeks; the National Cancer Institute-Fredrick 
Animal Production Area, USA) were anesthetized with 
pentobarbital sodium i.p (0.5 mg/1 gm of body weight; 
Nembutal (Abbott laboratories, USA) and placed in a 
supine position. A midline incision was made in the lower 
abdomen and the prostate was exteriorized. 25 μL of HBSS 
containing 125,000 PC3-P cells or (1.25 × 105, 2.5 × 105, 
5 × 105 or 1 × 106) PC3 Mig-3 cells were injected to the 
dorsolateral side of the prostate. The incision was closed 
with surgical metal clips (Braintree Scientific, Inc, USA).
Statistical analyses
ANOVA and Tukey’s test was conducted to compare 
differences in tumor weight and incidence of lymph node 
metastasis. Mann-Whitney U-test was conducted to 
compare differences in speed of migration using time-
lapse microscopy. Survival analysis was performed 
using Kaplan-Meier curves and statistical significance 
was assessed by Log-rank’s test. Unpaired Student’s 
t-test was conducted to compare the differences in all 
other assays. All the statistical analyses were performed 
with the GraphPad Prism software (version 6; GraphPad 
Software, USA).
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